This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Brimonidine topical


Topical gel containing brimonidine

Drugs List

  • brimonidine 3mg/g gel
  • MIRVASO 3mg/g gel
  • Therapeutic Indications


    Treatment of Rosacea (topical)


    One application per 24 hours of a small pea size amount of medicinal product to each of the five areas of the face: forehead, chin, nose, each cheek.

    The maximum daily recommended dose is 1 gram of gel in total weight.

    Initiate treatment with the smallest amount of gel for at least 1 week, then gradually increase dose based on individual response to treatment.

    Brimonidine gel should be applied smoothly and evenly as a thin layer.


    Children under 18 years

    Precautions and Warnings


    Contains parabens
    Contains propylene glycol: may cause irritation
    Advise patient to wash hands after use
    Avoid contact with eyes, lips or mouth
    Avoid contact with mucous membranes
    Avoid laser treatment or chemical peel before or after the treatment
    Do not apply to broken or denuded skin
    Do not apply to periorbital skin
    Discontinue if erythema worsens
    Discontinue treatment if severe irritation or contact allergy occurs
    Maintain treatment at the lowest effective dose
    Start treatment at lowest recommended dose
    Advise patient that the effects of alcohol may be potentiated
    Patients should not exceed recommended dose

    The effects of brimonidine topical gel begins to diminish hours after application. In some patients, erythema and flushing were reported to return with greater severity than was present at baseline. Most of the cases were observed within the first 2 weeks of starting the treatment.

    The onset of flushing relative to application of brimonidine gel varied, ranging from approximately 30 minutes to several hours.

    In the majority of cases, erythema and flushing resolved after discontinuation of brimonidine topical gel.

    If worsening erythema occurs, brimonidine topical gel should be discontinued symptomatic measures, such as cooling, NSAID and antihistamines, may help in alleviating symptoms.

    Prior to resuming treatment after temporary discontinuation due to aggravated erythema or flushing, perform a test application on a small area of the face for at least one day before full facial application is resumed.

    Pregnancy and Lactation


    Brimonidine gel should be used with caution in pregnancy.

    There are no or limited amount of data from the use of brimonidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. The manufacturer recommends avoiding brimonidine gel in pregnancy.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Brimonidine gel is contraindicated in breastfeeding.

    It is unknown whether brimonidine/metabolites are excreted in human milk. As a risk to the newborns/infants cannot be excluded the manufacturer recommends brimonidine gel is not used during breastfeeding.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at


    Brimonidine gel can be used in conjunction with other cutaneous medicinal products for the treatment of inflammatory lesions of rosacea and with cosmetics. These products should not be applied immediately before the daily application of brimonidine gel, they may be used only after the applied brimonidine gel has dried.

    Side Effects

    Allergic contact dermatitis
    Burning sensation
    Contact dermatitis
    Dry skin
    Eyelid oedema
    Feeling hot
    Nasal congestion
    Peripheral coldness
    Skin discomfort
    Skin irritation
    Skin pain


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: March 2014

    Reference Sources

    Summary of Product Characteristics: Mirvaso Gel 3mg/g. Galderma. Revised January 2017 .

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.